Effect of human albumin on TCD vasospasm, DCI, and cerebral infarction in subarachnoid hemorrhage: the ALISAH study.
Effect of human albumin on TCD vasospasm, DCI, and cerebral infarction in subarachnoid hemorrhage: the ALISAH study.
复制标题
DOI：
10.1007/978-3-319-04981-6_48
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
J. Suarez;R. Martin;E. Calvillo;E. Bershad;C. V. Venkatasubba Rao
中科院分区：
文献类型：
--
作者：
J. Suarez;R. Martin;E. Calvillo;E. Bershad;C. V. Venkatasubba Rao
背景和目的：人白蛋白的神经保护作用已在中风动物模型和患有各种颅内疾病的人类中进行了研究。我们研究了 25% 人白蛋白 (ALB) 对平均脑血流速度 (MCBFV)、迟发性脑缺血 (DCI) 和脑梗塞的影响。方法：我们研究了蛛网膜下腔出血白蛋白 (ALISAH) 试点临床试验的患者。我们收集了 90 天时通过经颅多普勒超声 (TCD) 测量的 MCBFV、DCI 发生率以及头部计算机断层扫描 (CT) 扫描脑梗死的数据。结果：TCD 在剂量层中 75 % (n= 15)、55 % (n= 11) 和 29 % (n= 2) 的受试者显示血管痉挛分别为 1、2 和 3。在剂量层 1、2 和 3 中，DCI 分别存在于 20% (n=≥4)、15% (n=≥3) 和 14% (n=≥1) 的受试者中。在 1 级、2 级和 3 级剂量下进行头部 CT 扫描的受试者中，脑梗塞的发生率分别为 45%（9 人中的 5 人）、27%（18 人中的 3 人）和 25%（4 人中的 1 人）。结论：较高剂量的 ALB 与 90 天时 TCD 血管痉挛、DCI 和脑梗死的发生率较低相关。剂量依赖性方式。
Background and Purpose: The neuroprotective effects of human albumin have been studied in animal models of stroke and in humans with various intracranial disorders. We investigated the effect of 25 % human albumin (ALB) on mean cerebral blood flow velocities (MCBFV), delayed cerebral ischemia (DCI), and cerebral infarction.Methods: We studied patients from the Albumin in Subarachnoid Hemorrhage (ALISAH) pilot clinical trial. We collected data on MCBFV as measured by transcranial Doppler ultrasound (TCD), incidence of DCI, and cerebral infarctions on head computed tomography (CT) scan at 90 days.Results: TCD showed vasospasm in 75 % (n= 15), 55 % (n= 11), and 29 % (n= 2) of subjects in dosage tiers 1, 2, and 3, respectively. DCI was present in 20 % (n= 4), 15 % (n= 3), and 14 % (n= 1) of subjects in dosage tiers 1, 2, and 3, respectively. Cerebral infarctions were seen in 45 % (5 of 9), 27 % (3 of 18), and 25 % (1 of 4) of subjects who had follow-up head CT scans in dosage tiers 1, 2, and 3, respectively.Conclusions: Higher dosages of ALB were associated with a lower incidence of TCD vasospasm, DCI, and cerebral infarction at 90 days in a dose-dependent manner.